
| • |
Previously announced agreement with the U.S. Food and Drug Administration (FDA) on the path forward for the potential full approval of belapectin. Alignment was reached with the agency on the key elements of the planned Phase 3 trial
design, including the primary endpoint of composite liver outcome, blinded central review process for endoscopic assessment of esophageal varices, and the use of a single, 2 mg/kg LBM dose of belapectin. Registrational Phase 3 trial
protocol submission for belapectin in advanced MASH cirrhosis with portal hypertension was filed with FDA in 3Q 2026.
|
| • |
Presented oral and poster presentations of new analyses from its global NAVIGATE Phase 2b/3 trial of belapectin at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in
Denver:
|
|
o
|
The oral presentation, presented by Naim Alkhouri, MD, FAASLD, Chief Medical Officer of Summit Clinical Research and Director of Steatotic Liver Program at Clinical Research Institute of Ohio, showed the potential utility of
ANTICIPATE-NASH risk stratification, a validated noninvasive tool to predict variceal development and assess belapectin treatment effect. In the NAVIGATE trial, belapectin treatment was associated with a favorable shift toward lower
ANTICIPATE-NASH predicted clinically significant portal hypertension (CSPH) risk at 18 months, with a net 15.9% placebo-adjusted improvement (p=0.04). Variceal incidence increased with higher CSPH probability yet was consistently lower in
patients treated with belapectin vs placebo across all baseline risk categories. The findings suggest that belapectin may reduce CSPH risk and potentially future hepatic decompensation.
|
| • |
Poster of Distinction: Baveno and ELF Risk Stratification in the NAVIGATE Trial
|
|
o
|
Baveno VII criteria and ELF score enable risk stratification for CSPH and risk of decompensation, respectively. This Poster of Distinction highlighted the relationship between baseline Baveno VI and ELF risk categories and incidence of
varices and belapectin treatment effect.
|
| • |
Poster Presentation: Baveno VII and ANTICIPATE-NASH in the Phase 2b GT-026 Trial
|
|
o
|
This poster presentation provided an overview of the analysis evaluating the correlation between Baveno VII criteria and ANTICIPATE-NASH, two noninvasive tests, with actual HVPG results the invasive gold standard for portal hypertension
measurement. Both noninvasive tests showed moderate agreement with HVPG-defined CSPH in patients with compensated MASH cirrhosis. Baveno VII demonstrated slightly better concordance and broader risk stratification than ANTICIPATE-NASH.
Together, results suggest that noninvasive tools can be used to identify CSPH and enrich the clinical trial population in MASH cirrhosis.
|
| • |
Richard E. Uihlein, the Company’s Chairman of the Board and largest stockholder, has converted all outstanding principal and accrued interest under five of the Company’s line of credit facilities into shares of the Company’s common
stock, effective July 31, 2026. The transaction simplifies Galectin’s capital structure and strengthens its balance sheet. Terms of the transaction include:
|
|
o
|
Elimination of approximately $105.8 million in total debt, consisting of $91.0 million in principal and $14.8 million in accrued interest
|
|
o
|
Issuance of 34,376,167 shares of common stock to Mr. Uihlein upon conversion
|
|
o
|
Conversion covers all notes under five of six credit facilities; the December 2025 facility remains undrawn and available
|
| • |
As of September 30, 2026, the Company had $11.7 million of cash and cash equivalents. Additionally, the Company has $10 million remaining available under a line of credit provided by its Chairman of the Board to fund operations. The
Company believes it has sufficient cash to fund currently planned operations and research and development activities through June 2027.
|
| • |
Research and development expenses for the quarter ended September 30, 2026 were $1.6 million compared with $2.6 million for the same period in 2025. The decrease was primarily due to timing of incurrence of expenditures related to our
NAVIGATE clinical trial.
|
| • |
General and administrative expenses for the quarter ended September 30, 2026 were $1.8 million, compared to $1.6 million for the quarter ended September 30, 2025. The increase was primarily due to an increase in non-cash, stock-based
compensation expense.
|
| • |
For the quarter ended September 30, 2026, the Company reported a net loss applicable to common stockholders of $3.6 million, or ($0.04) per share, compared to a net loss applicable to common stockholders of $8.2 million, or ($0.13) per
share for the quarter ended June 30, 2025. The decrease in net loss applicable to common stockholders was primarily due to the charge for change in fair value of derivative liabilities and decreased interest expense the quarter ended
September 30, 2026.
|
| • |
These results are included in the Company's Quarterly Report on Form 10-Q as of and for the
period ended September 30, 2026, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov.
|
|
Three Months Ended
September 30,
|
||||||||
|
2026
|
2025
|
|||||||
|
Operating expenses:
|
||||||||
|
Research and development
|
$
|
1,564
|
$
|
2,611
|
||||
|
General and administrative
|
1,803
|
1,587
|
||||||
|
Total operating expenses
|
3,367
|
4,198
|
||||||
|
Total operating loss
|
(3,367
|
)
|
(4,198
|
)
|
||||
|
Other income (expense):
|
||||||||
|
Interest income
|
28
|
39
|
||||||
|
Interest expense
|
(786
|
)
|
(1,820
|
)
|
||||
|
Change in fair value of derivatives
|
594
|
(2,205
|
)
|
|||||
|
Total other income
|
(164
|
)
|
(3,986
|
)
|
||||
|
Net loss
|
$
|
(3,531
|
)
|
$
|
(8,184
|
)
|
||
|
Preferred stock dividends
|
(37
|
)
|
(39
|
)
|
||||
|
Net loss applicable to common stock
|
$
|
(3,568
|
)
|
$
|
(8,223
|
)
|
||
|
Basic and diluted net loss per share
|
$
|
(0.04
|
)
|
$
|
(0.13
|
)
|
||
|
Shares used in computing basic and diluted net loss per share
|
89,621
|
64,205
|
||||||
|
September 30, 2026
|
December 31, 2025
|
|||||||
|
(in thousands)
|
||||||||
|
Cash and cash equivalents
|
$
|
11,706
|
$
|
17,720
|
||||
|
Total assets
|
13,009
|
19,532
|
||||||
|
Total current liabilities
|
46,406
|
8,030
|
||||||
|
Total liabilities
|
46,448
|
145,727
|
||||||
|
Total redeemable, convertible preferred stock
|
1,723
|
1,723
|
||||||
|
Total stockholders’ deficit
|
$
|
(35,162
|
)
|
$
|
(127,918
|
)
|
||